GEN RX INC Form 8-K December 31, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549		

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 31, 2007	

GEN/RX, INC.

(Exact Name of Registrant as Specified in Charter)

New York	0-24496	` 1 5	
(State or Other Jurisdiction	(Commission		
of Incorporation)	File Number)		
600 Woodmere Boulevard			44.500
Woodmere, New York			11598
(Address of Principal Executive Office	s)	(Zip Code)	
Registrant s telephone number, includ	ing area code: (516) 569-3800		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Edgar Filing: GEN RX INC - Form 8-K

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: GEN RX INC - Form 8-K

Item 8.01 Other Events

On December 31, 2007, Gen/Rx, Inc. (Gen/Rx) issued a press release announcing that it had filed a Form 15 to voluntarily deregister its common stock with the Securities and Exchange Commission. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release issued December 31, 2007.

2

Edgar Filing: GEN RX INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 31, 2007 GEN/RX, INC.

By: /s/ Jack Margareten

Jack Margareten Acting President and Chief Executive Officer

_